Due to the low number of events, we did not perform an analysis for the single causes of death, but only for liver‐related (including both HCC progression and underlying liver disease), which confirmed the previous findings: patients with CD4 + ≥ 200/mm3 had a median OS of 88 (IQR 15‐NR) months vs. 27 (IQR 22–42) months in those with lower CD4+, p = 0.04. This evidence concerns the gene CD4 and hepatocellular carcinoma.